Emcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivity gains. Net profit saw a significant 36.2% rise during the period. The company began its five-year plan on a strong footing for FY27. Emcure also completed the acquisition of a minority stake in Gennova Biopharmaceuticals.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.